109 results on '"van Hout, Ben A."'
Search Results
2. Exploring health preference heterogeneity in the UK: Using the online elicitation of personal utility functions approach to construct EQ‐5D‐5L value functions on societal, group and individual level
3. Using the Online Elicitation of Personal Utility Functions (OPUF) approach to derive a patient-based EQ-5D-5L value set: a study in 122 patients with rheumatic diseases from Germany
4. Hypothetical versus experienced health state valuation: a qualitative study of adult general public views and preferences
5. The Online Elicitation of Personal Utility Functions (OPUF) tool: a new method for valuing health states
6. Correction to: An Innovative Approach to Modelling the Optimal Treatment Sequence for Patients with Relapsing–Remitting Multiple Sclerosis: Implementation, Validation, and Impact of the Decision-Making Approach
7. An Innovative Approach to Modelling the Optimal Treatment Sequence for Patients with Relapsing–Remitting Multiple Sclerosis: Implementation, Validation, and Impact of the Decision-Making Approach
8. Mapping EQ-5D-3L to EQ-5D-5L
9. Critical appraisal and issues regarding generalisability of comparative effectiveness studies of NOACs in atrial fibrillation and their relation to clinical trial data: a systematic review
10. Mortality Prediction of the CHA2DS2-VASc Score, the HAS-BLED Score, and Their Combination in Anticoagulated Patients with Atrial Fibrillation
11. Cost-effectiveness of proprotein convertase subtilisin/kexin type 9 inhibition with evolocumab in patients with a history of myocardial infarction in Sweden
12. Impact of Patient Characteristics on Treatment Outcomes in Symptomatic Venous Thromboembolism: Results of HOKUSAI-VTE Randomized Trial Analysis
13. The EQ-5D-5L Value Set for England: Response to the “Quality Assurance”
14. Some considerations concerning negative values for EQ-5D health states
15. Methodology of a Novel Risk Stratification Algorithm for Patients with Multiple Myeloma in the Relapsed Setting
16. Updated Cost-effectiveness Analysis of Evolocumab in Patients With Very High-risk Atherosclerotic Cardiovascular Disease
17. An updated cost-effectiveness analysis of evolocumab therapy for reducing cardiovascular events in very high-risk patients with atherosclerotic cardiovascular disease according to the 2018 ACC/AHA guideline
18. Health-related quality of life and mortality in patients with pulmonary embolism: a prospective cohort study in seven European countries
19. Comparison of quality of life measurements: EQ-5D-5L versus disease/treatment-specific measures in pulmonary embolism and deep vein thrombosis
20. Overview, Update, and Lessons Learned From the International EQ-5D-5L Valuation Work: Version 2 of the EQ-5D-5L Valuation Protocol
21. Pulmonary embolism in Europe - Burden of illness in relationship to healthcare resource utilization and return to work
22. The impact of co-morbidity on the disease burden of VTE
23. A new method for valuing health: directly eliciting personal utility functions
24. An exploration of the non‐iterative time trade‐off method to value health states
25. Correction to: Comparing the UK EQ-5D-3L and English EQ-5D-5L Value Sets
26. Comparing the UK EQ-5D-3L and English EQ-5D-5L Value Sets
27. Cost-effectiveness of edoxaban compared to warfarin for the treatment and secondary prevention of venous thromboembolism in the UK
28. International Regulations and Recommendations for Utility Data for Health Technology Assessment
29. Sourcing and Using Appropriate Health State Utility Values in Economic Models in Health Care
30. Cost-effectiveness of Evolocumab Therapy for Reducing Cardiovascular Events in Patients With Atherosclerotic Cardiovascular Disease
31. Valuing health-related quality of life: An EQ-5D-5L value set for England
32. New methods for modelling EQ-5D-5L value sets: An application to English data
33. The Importance of Economic Perspective and Quantitative Approaches in Oncology Value Frameworks of Drug Selection and Shared Decision Making
34. OBSERVED VERSUS PREDICTED CARDIOVASCULAR EVENT RATES IN PRIMARY PREVENTION DIABETIC PATIENTS RECEIVING HIGH-INTENSITY STATINS IN THE UNITED KINGDOM
35. Cost‐Effectiveness of LDL‐C Lowering With Evolocumab in Patients With High Cardiovascular Risk in the United States
36. Cost-effectiveness of ocriplasmin for the treatment of vitreomacular traction and macular hole
37. Cost-effectiveness Analysis of Rivaroxaban in the Secondary Prevention of Acute Coronary Syndromes in Sweden
38. The Continuing Story of the Cost-Effectiveness of Photoselective Vaporization of the Prostate versus Transuretheral Resection of the Prostate for the Treatment of Symptomatic Benign Prostatic Obstruction
39. A Comparison of Methods for Converting DCE Values onto the Full Health-Dead QALY Scale
40. Multinational Evidence of the Applicability and Robustness of Discrete Choice Modeling for Deriving EQ-5D-5L Health-State Values
41. A Program of Methodological Research to Arrive at the New International EQ-5D-5L Valuation Protocol
42. Assessing Uncertainties Surrounding Combined Endpoints for Use in Economic Models
43. Eliciting health state utilities for Dupuytren’s contracture using a discrete choice experiment
44. Estimating Preference-Based EQ-5D Health State Utilities or Item Responses from Neuropathic Pain Scores
45. Estimating Preference-Based EQ-5D Health State Utilities or Item Responses from Neuropathic Pain Scores
46. Interim Scoring for the EQ-5D-5L: Mapping the EQ-5D-5L to EQ-5D-3L Value Sets
47. A COMPARISON OF ALTERNATIVE VARIANTS OF THE LEAD AND LAG TIME TTO
48. Estimating Preference-Based Single Index Measures for Dementia Using DEMQOL and DEMQOL-Proxy
49. Quality of Life After PCI With Drug-Eluting Stents in Coronary Artery Bypass Surgery
50. Economic outcomes of percutaneous coronary intervention with drug-eluting stents versus bypass surgery for patients with left main or three-vessel coronary artery disease: One-year results from the SYNTAX trial
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.